Journal: Diabetes, Obesity & Metabolism

Article Title: Time in range—A new gold standard in type 2 diabetes research?

doi: 10.1111/dom.16279

Figure Lengend Snippet: Studies involving time in range as an outcome measure in people with type 2 diabetes.

Article Snippet: Sheyda Sofizadeh et al. (2019) , Sweden , N = 124, Type 2 diabetes, double‐blind, placebo‐controlled trial with a parallel‐group design , Primary , Yes , Liraglutide vs. Placebo , Dexcom G4 , 24 weeks , Mean time in target range was higher in the liraglutide group than in the placebo group: 430 versus 244 min/24 h ( p < 0.001) and 960 versus 695 min/24 h ( p < 0.001) for the two glycaemic ranges considered, 4–7 mmol/L and 4–10 mmol/L, respectively. HbA1c was also significantly lower in the liraglutide group. Mean time in hypoglycaemia was similar for participants receiving liraglutide and those receiving placebo after 24 weeks of treatment..

Techniques: Control, Standard Deviation, Derivative Assay, Comparison, Analogues, Medications, Clinical Proteomics, Titration, Starch

Journal: IEEE transactions on bio-medical engineering

Article Title: A Review of Emerging Technologies for the Management of Diabetes Mellitus

doi: 10.1109/TBME.2015.2470521

Figure Lengend Snippet: Technical Specifications and Accuracy of Commercially Available CGMS [ 20 ]

Article Snippet: The clinically accepted zones are considered to be zones A and B. table ft1 table-wrap mode="anchored" t5 TABLE I caption a7 Device Technology Sensor Lifespan Sensor Warm-Up Calibration Records Frequency Accuracy Reference Dexcom Seven Plus (Dexcom) Invasive 168 h 2 h every 12 h 5 min MARD: 16% MAD in hypoglycemia: 16 mg/dL YSI blood glucose analyzer Dexcom G4 Platinum (Dexcom) Invasive 168 h 2 h every 12 h 5 min MARD: 13% MAD in hypoglycemia: 11 mg/dL YSI blood glucose analyzer Guardian Real-Time (Medtronic) Invasive 72 h 2 h every 12 h 5 min MARD: 17.6% EGA (A+B): 99.6% Arterial samples FreeStyle Navigator (Abbott) Invasive 120 h 10 h calibration at 10 h, 12 h, 24 h and 72 h. 1 min MARD: 12.8% MedARD: 9.3% EGA (A+B): 98.4% YSI blood glucose analyzer FreeStyle Navigator II (Abbott) Invasive 120 h 10 h calibration at 10 h, 12 h, 24 h and 72 h. 1 min HG1-c (C8 Medisensors) Non Invasive(Raman spectroscopy) – – 5 min MARD: 38 mg/dL MedARD: 30 mg/dL EGA (A+B): 92% Blood glucose reference values GlucoTrack (Integrity Applications Ltd.) Non Invasive (thermal ultrasound and electromagnetic) 6 months (ear clip lifespan) – Every 6 months (for a new ear clip) MARD: 29.9% MedARD : 19.9% EGA (A+B): 92% Commercial glucose meter and glucose analyzer Symphony (Echo Therapeutics Inc) Prelude SkinPrep System – – 1 min EGA (A+B): 96.9% YSI 2300 STAT Plus glucose analyzer and commercial glucose meters Open in a separate window Technical Specifications and Accuracy of Commercially Available CGMS [ 20 ] The latest technological advances are focused on less invasive techniques (e.g., microneedles), noninvasive techniques based on optical methods (e.g., kromoscopy, Raman Spectroscopy, NIR Spectroscopy, and Photoacoustic Spectroscopy) and transdermal methods (e.g., reverse iontophoresis and sonophoresis) [ 22 ].

Techniques: Spectroscopy